Eosinophilic granulomatosis with polyangiitis (EGPA), also known as Churg-Strauss syndrome, is a rare and complex disease belonging to the group of systemic vasculitides. It is characterized by inflammation of blood vessels, especially small and medium-sized ones, and is often accompanied by damage to various organs, including the lungs, kidneys, and nervous system. The main pathogenetic mechanism of EGPA is an allopathic reaction that leads to an increase in the level of eosinophils in the blood, which, in turn, causes the development of granulomatous changes. Clinical manifestations of the disease vary from mild to severe and may include respiratory symptoms, skin rashes, hematuria, and neuropathy.
History of the disease and interesting historical facts
The history of EGPA research dates back to the mid-20th century. The first detailed descriptions of the disease were made in 1951, when physicians noticed the association between eosinophilia and vasculitis. The name Churg-Strauss syndrome was introduced in 1951 and became widely used after the description of clinical cases demonstrating typical symptoms of the disease, including asthma, sinusitis, and systemic manifestations. Interestingly, this disease was later reinterpreted in the context of allergies and autoimmune reactions, which clearly demonstrates the multifactorial nature of EGPA.
Epidemiology
According to international data, the incidence of EGPA ranges from 0.1 to 3 cases per 100,000 population per year. The disease most often occurs in young and middle-aged people, with a peak incidence between the ages of 30 and 60. Some studies indicate a higher incidence in men, although general trends indicate that gender differences are not so pronounced. EGPA is often found in populations with a high level of allergic diseases, which may indicate possible pathogenetic links.
Genetic predisposition to this disease
Research has linked EGPA to certain genetic markers, particularly mutations in genes involved in the immune response. The HLA-DRB1 gene, which plays an important role in antigen presentation, has been linked to an increased susceptibility to the disease. Numerous other genes and polygenic variants, including those associated with inflammation and allergic reactions, have also been implicated. Further research is needed to better understand the genetic architecture of EGPA.
Risk factors for the development of this disease
Specific risk factors for EGPA have not been fully identified, however, there are several aspects that may contribute to its development:
- Environmental factors: Exposure to toxic substances such as heavy metals and solvents may be associated with the development of the disease.
- Infectious agents: Some infections are thought to act as triggers for the inflammatory process.
- Allergic reactions: Patients with pre-existing allergic diseases may have a higher risk of developing EGPA.
Diagnosis of this disease
Diagnosis of EGPA requires a comprehensive approach, including both clinical observations and laboratory research methods:
- Major symptoms of the disease may include: asthma, chronic sinusitis, eosinophilia, skin rashes and nephropathy.
- Laboratory tests: elevated blood eosinophils, antinuclear antibodies, and a positive anti-MPO-ANA test result.
- Radiological examinations: ultrasound, CT and MRI to detect damage to organs such as the lungs and kidneys.
- Differential diagnosis: it is necessary to exclude other systemic vasculitis, infectious diseases and allergic reactions.
Treatment
Treatment of EGPA is evolving and may include different approaches, from conservative therapy to more aggressive interventions:
- General treatment includes corticosteroids, which may be used to control the inflammatory process.
- Pharmacological treatment includes immunosuppressants such as methotrexate and azathioprine to suppress the activity of the autoimmune response.
- Surgical treatment may be indicated in case of serious complications, such as necrotizing glomerulonephritis.
- Other treatments may include plasmapheresis and the use of biologic therapy such as rituximab.
List of medications used to treat this disease
The following groups of drugs are used in the treatment of EGPA:
- Corticosteroids (prednisolone, dexamethasone).
- Immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil).
- Biological drugs (rituximab, tocilizumab).
- Antibiotics to prevent infections.
Disease monitoring
Monitoring of EGPA is critical to assess response to treatment and prevent relapse:
- Control stages: regular checks of eosinophil levels, kidney function and general clinical symptoms.
- Prognosis: With adequate treatment, remission and improved quality of life are possible.
- Complications: development of chronic renal failure, pulmonary fibrosis and neuropathy may occur.
Age-related features of the disease
EGPA may manifest itself differently in different age groups. In children, the disease usually proceeds with less pronounced symptoms and reactions. In older people, the risk of developing severe forms of the disease increases, which is associated with the presence of concomitant diseases and decreased immune activity. It should be noted that juvenile EGPA is observed less frequently and requires special attention to therapeutic approaches.
Questions and Answers
- What are the main symptoms of EGPA? Symptoms include asthma, chronic sinusitis, skin rashes, nephropathy and eosinophilia.
- How is EGPA diagnosed? Diagnosis includes blood tests for eosinophils, tests for antibodies, and radiological studies.
- How is EGPA treated? Treatment may include corticosteroids, immunosuppressants, and in some cases biological therapy.
- What is the prognosis for patients with EGPA? With timely and adequate treatment, many patients achieve remission and have a good prognosis.
- Are there any risk factors for developing EGPA? Yes, these can be allergic reactions, exposure to toxic substances and infections.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov emphasizes the importance of timely diagnosis and an individual approach to the treatment of EGPA. He recommends to patients:
- Undergo regular check-ups and monitor your own health.
- Discuss all manifestations of the disease with your doctor and respond to changes in your condition.
- Avoid contact with potential allergens and toxic substances.
- Maintain a healthy lifestyle: Eating right and being physically active can improve your quality of life.
- Be armed with information about the disease to be prepared for possible changes during therapy.
